Abstract

Whole-exome sequencing (WES) in biobank initiatives has emerged as a transformative tool for advancing 
genomic research and precision medicine. By capturing all protein-coding regions of the human genome, WES 
enables the identification of genetic variants that inform disease mechanisms, risk prediction, and therapeutic 
strategies. However, the integration of WES into biobanking raises profound ethical, legal, and social implications 
(ELSI), particularly in relation to informed consent, data governance, privacy, incidental findings, equity, and 
public trust. This paper provides a comprehensive analysis of ELSI in WES biobanks, examining technical 
considerations, consent validity over time, governance structures, data security, and dynamic consent models. 
Comparative case studies highlight challenges in legal compliance, data sharing, and stakeholder engagement, 
emphasizing the importance of transparency, community involvement, and adaptive governance frameworks. 
Future directions include federated and privacy-preserving data-sharing architectures, harmonized standards, and 
innovative consent mechanisms that balance scientific advancement with societal responsibility. Ultimately, 
effective governance, ethical stewardship, and inclusive public engagement are essential for sustaining biobank 
initiatives, mitigating health disparities, and fostering public trust in genomic research.